Engineered immune cells aim to stop relapse in young blood cancer patients
NCT ID NCT07476027
First seen Mar 24, 2026 · Last updated May 21, 2026 · Updated 13 times
Summary
This early-phase trial tests a new treatment called CD7 CAR-T cell therapy for 10 children with high-risk T-cell leukemia or lymphoma. After initial chemotherapy puts the cancer into remission, the child's own immune cells are collected, engineered to target cancer cells, and given back. The goal is to see if this approach is safe and can prevent the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.